Related Experiment Videos
[How to treat tumor-induced hypercalcemia]
1Clinique des soins supportifs et clinique d'endocrinologie/maladies osseuses, Service de médecine interne, Institut Jules Bordet, Université libre de Bruxelles, B-1000 Bruxelles. jj.body@bordet.be
La Revue Du Praticien
|March 11, 2004
Summary
Cancer hypercalcemia is treatable in over 90% of cases using bisphosphonates like zoledronic acid. Long-term bisphosphonate therapy also helps prevent hypercalcemia in patients with bone metastases.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Context:
- Cancer hypercalcemia is a common complication of advanced malignancies.
- Effective management is crucial for patient quality of life and treatment outcomes.
Purpose:
- To review current and potential therapeutic strategies for managing cancer hypercalcemia.
- To highlight the efficacy and safety profiles of various bisphosphonates and future treatment avenues.
Summary:
- Cancer hypercalcemia is successfully managed in at least 90% of cases with standard therapy, including rehydration and bisphosphonates.
- Pamidronate and zoledronic acid are standard treatments, with zoledronic acid being more potent. Ibandronate offers an alternative with potentially lower nephrotoxicity.
- Recurrent hypercalcemia in advanced stages remains challenging, but future therapies like anti-PTHrP antibodies may offer solutions.
Impact:
- Current therapies provide effective control of cancer hypercalcemia, improving patient prognosis.
- Long-term bisphosphonate use in bone metastasis management can prevent hypercalcemia, reducing overall complications.
- Advancements in treatment, including novel antibodies, promise improved outcomes for difficult-to-treat cases.